ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Gene therapy start-up Freeline Therapeutics raises $116 million

by Ryan Cross
June 24, 2018 | APPEARED IN VOLUME 96, ISSUE 26

09626-buscon16-cgt.jpg
Credit: Cell & Gene Therapy Catapult
Freeline partnered with the U.K.'s Cell & Gene Therapy Catapult to manufacture its AAV-based gene therapies.

The U.K-. and Germany-based gene therapy start-up Freeline Therapeutics has raised $116 million in series B financing, most of it coming from British life sciences investment company Syncona. Freeline will use the money to develop adeno-associated virus (AAV) gene therapies for hemophilia B, caused by a deficiency in clotting factor IX, and for Fabry disease, caused by a deficiency of a lipid-metabolizing enzyme. Gene therapy clinical trials for those diseases are already under way at competitors Spark Therapeutics and Avrobio.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment